KalVista Pharmaceuticals/$KALV

KalVista shares are trading lower following the company's FY25 financial results and operational update.
60 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Ticker

$KALV
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

150

ISIN

US4834971032
Website
www.kalvista.com

KALV Metrics

BasicAdvanced
$771M
-
-$3.69
-
-

What the Analysts think about KALV

Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.

Bulls say / Bears say

The FDA's approval of KalVista's Ekterly as the first oral on-demand treatment for hereditary angioedema (HAE) positions the company as a leader in this niche market, potentially capturing significant market share. (reuters.com)
Analysts estimate peak U.S. sales of Ekterly at around $250 million, indicating strong revenue potential due to early launch, premium pricing, and rapid adoption. (reuters.com)
KalVista's licensing agreement with Pendopharm to commercialize sebetralstat in Canada expands its market reach, potentially increasing revenue streams. (businesswire.com)
The FDA's extended review of sebetralstat due to heavy workload and limited resources could delay market entry, affecting revenue timelines. (reuters.com)
KalVista's recent $55 million underwritten offering and $5 million private placement may lead to shareholder dilution, potentially impacting stock value. (businesswire.com)
Insider selling, such as the Chief Development Officer's sale of $19,218 in stock, might signal concerns about the company's future performance. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

KALV Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KALV Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

KALV News

AllArticlesVideos
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

Business Wire·1 day ago
US FDA approves KalVista Pharma's swelling disorder drug

US FDA approves KalVista Pharma's swelling disorder drug

Reuters·4 days ago
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KALV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs